November 25, 2025 — Leads & Copy — Global allogeneic cellular medicine leader Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today released a trading update and operational overview as part of the Chief Executive’s Annual General Meeting (AGM) address.
Management anticipates gross revenue exceeding US$30.0 million from sales of Ryoncil® (remestemcel-L-rknd) for the quarter ending December 31, 2025. This would represent a more than 37% increase compared to the US$21.9 million in gross revenue from Ryoncil® in the prior quarter, which ended September 30, 2025.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell (MSC) therapy, indicated for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older. The full Prescribing Information can be found at www.ryoncil.com.
The company is also focused on developing additional cell therapies for various indications, utilizing its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is under development for SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, while Rexlemestrocel-L is being developed for heart failure and chronic low back pain. Mesoblast has established commercial partnerships in Japan, Europe, and China.
Mesoblast has a global intellectual property portfolio encompassing over 1,000 granted patents or patent applications related to mesenchymal stromal cell compositions, manufacturing methods, and indications. These patents and applications provide commercial protection through at least 2044 in major markets.
The company’s manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines, with defined pharmaceutical release criteria, readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO).
Paul Hughes
T: +61 3 9639 6036
Emma Neal
T: +1 603 545 4843
E: emma.neal@allisonworldwide.com
Steve Dabkowski
T: +61 419 880 486
E: steve@bluedot.net.au
Source: Mesoblast
